Stoke Therapeutics Q2 EPS USD -0.93

Stoke Therapeutics (NASDAQ: STOK) reported its second-quarter 2026 earnings on August 12, 2025, with an earnings per share (EPS) of -$0.40, which exceeded the consensus estimate of -$0.46 by $0.06. The company’s quarterly revenue was $13.82 million, below the estimated revenue of $31.51 million.

For the six months ended June 30, 2025, the company reported a net income of $89.4 million, or $1.50 per diluted share, compared to a net loss of $52.1 million, or $1.02 per share, for the same period in 2024. The year-to-date revenue was $172.39 million, driven by revenue from the License and Collaboration Agreement with Biogen, which contributed $155.6 million.

Research and development expenses for the three months ended June 30, 2025, were $25.9 million, compared to $21.1 million for the same period in 2024. General and administrative expenses were $15.3 million, up from $13.0 million in the prior year. The increase in operating expenses was attributed to higher personnel costs and launch readiness expenses.

As of June 30, 2025, Stoke Therapeutics had $355.0 million in cash, cash equivalents, and marketable securities, which the company anticipates will fund operations through mid-2028. The company also announced the initiation of the Phase 1 study (OSPREY) of STK-002 for the treatment of Autosomal Dominant Optic Atrophy (ADOA) and the first patient dosed in the global Phase 3 EMPEROR study of zorevunersen for Dravet syndrome.

The company’s upcoming earnings report for Q2 2026 is estimated to be released on August 11, 2026, with a conference call scheduled for 4:30 PM ET. Analysts currently estimate an EPS of -$0.80 for Q2 2026.

Stoke Therapeutics continues to focus on advancing its pipeline, with zorevunersen in Phase 3 trials for Dravet syndrome and STK-002 in Phase 1 trials for ADOA. The company’s financial position and clinical progress highlight its ongoing efforts to develop disease-modifying therapies for rare genetic disorders.